Literature DB >> 26917607

Idelalisib-related pneumonitis.

Eglantine Haustraete1, Julie Obert1, Samia Diab2, Sarah Abbes3, Jean-Marc Zini4, Sandrine Valade5, Nathalie Lerolle6, Nicolas Albin7, Bertrand Arnulf8, Jean-David Bouaziz9, Claire Hussenet1, Abdellatif Tazi10, Anne Bergeron11.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26917607     DOI： 10.1183/13993003.01670-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  8 in total

1.  An unusual case of Idelalisib-related pneumonitis with severe respiratory failure.

Authors:  Domingos Sousa; Maria Eduarda Couto; Alda Tavares; Teresa Ribeiro; Fabiana Santos Muñoz; Nelson Domingues; Isabel Oliveira; Mário Mariz
Journal:  EJHaem       Date:  2020-10-26

Review 2.  Idelalisib in the management of lymphoma.

Authors:  Chan Yoon Cheah; Nathan H Fowler
Journal:  Blood       Date:  2016-06-01       Impact factor: 22.113

Review 3.  Managing toxicities of phosphatidylinositol-3-kinase (PI3K) inhibitors.

Authors:  Ashley Hanlon; Danielle M Brander
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

4.  Incidence, clinical characteristics, and outcome of interstitial pneumonia in patients with lymphoma.

Authors:  Wei Ping Liu; Xiao Pei Wang; Wen Zheng; Yan Xie; Mei Feng Tu; Ning Jing Lin; Ling Yan Ping; Zhi Tao Ying; Chen Zhang; Li Juan Deng; Ning Ding; Xiao Gan Wang; Yu Qin Song; Jun Zhu
Journal:  Ann Hematol       Date:  2017-10-31       Impact factor: 3.673

Review 5.  Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.

Authors:  Iris de Weerdt; Suzanne M Koopmans; Arnon P Kater; Michel van Gelder
Journal:  Haematologica       Date:  2017-08-03       Impact factor: 9.941

Review 6.  New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.

Authors:  Frank Kroschinsky; Friedrich Stölzel; Simone von Bonin; Gernot Beutel; Matthias Kochanek; Michael Kiehl; Peter Schellongowski
Journal:  Crit Care       Date:  2017-04-14       Impact factor: 9.097

Review 7.  Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation.

Authors:  Babina Gosangi; Matthew Davids; Bhanusupriya Somarouthu; Francesco Alessandrino; Angela Giardino; Nikhil Ramaiya; Katherine Krajewski
Journal:  Cancer Imaging       Date:  2018-04-18       Impact factor: 3.909

Review 8.  Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.

Authors:  Antonio Cuneo; Giovanni Barosi; Romano Danesi; Stefano Fagiuoli; Paolo Ghia; Alfredo Marzano; Marco Montillo; Venerino Poletti; Pierluigi Viale; Pier Luigi Zinzani
Journal:  Hematol Oncol       Date:  2018-09-05       Impact factor: 5.271
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.